The specialist integrated CDMO

Browser not supported

Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:

Google Chrome
Safari
Firefox
Edge
© 2025 Hovione
  • Linkedin
  • Facebook
  • Twitter
  • Instagram
  • Youtube
search
    en
      pt jp cn
Hovione
Home Go up
  • Products and Services
      • Contract Manufacturing Services
        • Drug Substance
        • Particle Engineering
        • Drug Product
      • Off-patent API products
        • API Portfolio
        • Exclusive partnerships
        • High value applications
      • Supporting Capabilities
        • Analytical Support
        • Capabilities
        • Continuity of Supply
        • Quality and Compliance
  • Knowledge Center
  • About Us
      • About Hovione
        • What we do
        • Management
        • Sustainability
        • History
  • Contact Us
  • Press Room
  • Hovione Worldwide
  • Careers
  • Restricted Area

Search

Types

  • Article
  • Event
  • Page

Press Room

  • Press Release
  • Press Clipping
  • Article

Categories

  • Hovione New Jersey
  • Hovione Cork
  • Hovione Loures
  • Contract Manufacturing Services
  • DP - Drug product
  • PE - Particle Engineering
  • Hovione Japan
  • Hovione Mumbai
  • PE - Spray drying
  • Homepage
  • Hovione Macau
  • Off-patent API
  • Hovione Shanghai
  • DP - Inhalation formulation
  • Hovione Hong Kong
  • Hovione Switzerland
  • Integrated Offering
  • PE - Drug delivery platforms
  • About Hovione
  • Analytical support
  • Continuous Manufacturing
  • DP - DPI devices
  • DS - High potency handling
  • Hovione Lisboa
  • PE - Inhalable particles
  • PE - Spray congealing
  • R&D
  • (-) DS - Drug Substance
  • (-) Hovione Lumiar

Hovione Capacity Expansion

Hovione is Growing

View
Article / Sep 27, 2021

How the drug services industry found itself prepared for a pandemic

C&EN, 26 September 2021

Hovione Lumiar

Office and R&D Center

Continuous Flow

Expand the established chemistry space with Continuous Flow to deliver robust and sustainable processes.

View
Press Release / Sep 19, 2024

Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions

Commitment to partnership and joint innovation for cell and gene therapies

Pagination

  • First page « First
  • Previous page ‹‹
  • Page 1
  • Current page 2
Analytical Support
Quality and Compliance
Capabilities
Continuity of Supply
Track Record/cGMP Compliance
Regulatory Affairs
Continuity of Supply
  • Hovione Worldwide
  • Events
  • Press Room
  • Careers
  • Customers
  • Suppliers
Contacts
Lindenstrasse 14
6340 Baar
Switzerland
  • Linkedin
  • Facebook
  • Twitter
  • Instagram
  • Youtube
  • Privacy Notice
  • Terms and Conditions
    • Linkedin
    • Facebook
    • Twitter
    • Instagram
    • Youtube
  • Hovione Worldwide
  • Events
  • Press Room
  • Careers
  • Customers
  • Suppliers
  • Contacts
    Lindenstrasse 14
    6340 Baar
    Switzerland
    © 2025 Hovione
    © 2025 Hovione
    • Privacy Notice
    • Terms and Conditions